The ILux® compared to the mechanical meibomian gland expression for the treatment of moderate and severe meibomian gland dysfunction
Author:
Corresponding Author:

Maria Ximena Nu?ez. Unit of Cornea, Cataract and Refractive Surgery, Vision Sana Research Group, Clínica de Oftalmología de Cali, Faculty of Medicine Pontificia Universidad Javeriana Cali, Street 18 No. 118-250, Cali 760031, Colombia. ximena@visionsana.com

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To compare the safety and effectiveness of eyelid treatment with the ILux®-MGD Treatment System in one session versus five sessions of mechanical meibomian gland expression (MMGE) in patients with moderate to severe meibomian gland dysfunction (MGD). METHODS: A prospective, randomized, open-label, and controlled clinical trial that compared one session of the ILux® MGD Treatment System versus five sessions of MMGE in both eyes of 130 patients aged ≥18y with Ocular Surface Disease Index (OSDI) scores ≥13, total meibomian gland scores (MGS) of <15 in the lower eyelid of each eye, and non-invasive tear break-up time (NI-TBUT) <10s, who were randomized 1:1 to ILux® or MMGE. RESULTS: The mean age was 58±17.49y. Baseline total MGS scores in both treatment groups were comparable. During follow-up, there were significant differences in total MGS and per sector with P<0.001. Multivariate analysis was performed using generalized estimating equations corresponding to the generalized linear model for repeated means to determine the treatment relationship with total MGS, NIBUT, and OSDI. There was a significant difference between ILux® and MMGE (P<0.001) at follow-up from the first to the twelfth month in MGS, NI-BUT, and OSDI scores. No adverse events were reported. CONCLUSION: ILux® treatment compared to MMGE significantly improves symptoms and signs in patients with moderate to severe MGD for one year without adverse events.

    Reference
    Related
    Cited by
Get Citation

María Ximena Núñez, Andrea Acosta-Ortega, Guillermo Raul Vera-Duarte, et al. The ILux® compared to the mechanical meibomian gland expression for the treatment of moderate and severe meibomian gland dysfunction. Int J Ophthalmol, 2024,17(6):1042-1048

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:July 08,2023
  • Revised:March 06,2024
  • Adopted:
  • Online: May 24,2024
  • Published: